Bedrijfsoverzicht
Nuwellis, Inc. is a medical device company dedicated to the development, manufacturing, and commercialization of technologies utilized in ultrafiltration therapy for treating fluid overload conditions. The enterprise operates within the Healthcare sector, specifically focusing on the Medical Devices industry, where it aims to provide specialized solutions for patients suffering from heart failure complications. The company maintains a small operational footprint with a workforce of 38 employees and holds a market capitalization of $2.86M based on current trading valuations. Its annual revenue for the trailing twelve months stands at $8.27M, indicating that the firm functions as a micro-cap entity with limited scale relative to established industry peers. These valuation figures suggest that the market prices the stock with a significant discount, reflecting the high risk profile associated with small-cap medical device firms that are still establishing their commercial footprint and generating profitability.
Financiële gezondheid
For the trailing twelve months, the company reported revenue of $8.27M alongside a net income of $-17,517,000, revealing a substantial gap between top-line generation and bottom-line profitability that points to a highly aggressive or inefficient cost structure. The EBITDA for the period was $-10,906,000, which further underscores the operational challenges faced by the business in converting sales into cash-flow-positive operations before financing costs. Free cash flow stood at $-12,967,875, indicating that the company is currently burning cash and lacks the immediate financial flexibility to fund significant capital expenditures or acquisitions without external financing. Gross margin is reported at 62.0%, suggesting that the cost of goods sold is relatively contained compared to revenue, whereas the operating margin of -100.8% and profit margin of -211.9% demonstrate that overhead costs and other operating expenses significantly exceed gross profits. The balance sheet shows $1.08M in cash against $328,000 in debt, resulting in a debt-to-equity ratio of 12.47, which indicates a highly leveraged financial position where equity is insufficient to cover the reported debt obligations. Despite the high leverage, the current ratio of 1.71 suggests that the company possesses adequate short-term assets to cover its current liabilities, providing a layer of liquidity stability amidst operational losses. Return on Equity is calculated at -382.6% and Return on Assets at -86.9%, metrics that reveal that management has not yet achieved positive returns on the capital deployed by shareholders or the asset base, signaling ongoing struggles to generate efficient value from existing resources.
Waarderingsbeoordeling
The trailing P/E ratio is listed as N/A due to the negative earnings, while the forward P/E stands at -0.42, implying that the market currently prices in negative earnings expectations or that the stock is valued primarily on asset backing rather than earnings power. The price-to-book ratio is 0.70, which indicates that the market is valuing the company at a discount to its book value, suggesting a lack of market premium over the net asset position often seen in mature medical device firms. Alternative valuation metrics such as the price-to-sales ratio of 0.35 and an EV/EBITDA of -0.16 suggest that investors are pricing the stock based on revenue generation rather than profitability, a common characteristic for pre-profit growth companies in the medical technology space. The stock has a 52-week high of $45.36 and a 52-week low of $0.96, meaning the current trading price sits significantly below the recent peak and well above the absolute floor of the trading range. The beta value of 0.08 indicates that the stock exhibits extremely low volatility relative to the broader market, behaving more like a stable bond than a typical equity security in terms of price movement sensitivity to market swings.
Growth & Income
Revenue growth year-over-year is recorded at 4.4%, while earnings growth is listed as N/A due to the absence of positive earnings, implying that the company is prioritizing top-line expansion over immediate profit generation at this stage of its lifecycle. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all of its meager cash flows to reinvest into research, development, and commercialization efforts rather than distributing income to shareholders. The absence of a dividend policy aligns with the company's non-dividend payer status, where earnings are theoretically available for reinvestment, though the current negative net income limits the actual funds available for such reinvestment. Overall, the growth and income profile reflects a high-risk, non-dividend strategy focused on revenue expansion in a specialized niche, where profitability remains elusive despite modest revenue growth.